Characterization of adeno-associated viral vector (AAV) mediated gene delivery to the enteric nervous system (ENS) was recently described in mice and rats. In these proof-of-concept experiments, we show that intravenous injections of clinically relevant AAVs can transduce the ENS in guinea pigs and non-human primates. Neonatal guinea pigs were given intravenous injections of either AAV8 or AAV9 vectors that contained a green fluorescent protein (GFP) expression cassette or phosphate-buffered saline. Piglets were euthanized three weeks post injection and tissues were harvested for immunofluorescent analysis. GFP expression was detected in myenteric and submucosal neurons along the length of the gastrointestinal tract in AAV8 injected guinea pigs. GFP-positive neurons were found in dorsal motor nucleus of the vagus and dorsal root ganglia. Less transduction occurred in AAV9treated tissues. Gastrointestinal tissues were analyzed from young cynomolgus macaques that received systemic injection of AAV9 GFP. GFP expression was detected in myenteric neurons of the stomach, small and large intestine. These data demonstrate that ENS gene delivery translates to larger species. This work develops tools for the field of neurogastroenterology to explore gut physiology and anatomy using emerging technologies such as optogenetics and gene editing. It also provides a basis to develop novel therapies for chronic gut disorders.
INTRODUCTION
Gene delivery is an effective basic and translational tool to manipulate neurological behavior, inflammatory responses and degeneration that has only recently been explored for application to the enteric nervous system (ENS). [1] [2] [3] Efficiency is enhanced with the use of viral or non-viral vectors to facilitate nucleic acid uptake and stability. Viral vectors are commonly used in the central nervous system for basic and pre-clinical studies and have an excellent safety profile in clinical testing. [4] [5] [6] Delivery of vectors can involve direct injection of target structures, which can be invasive and challenging if transduction is required in neuronal networks that span a large area. It was shown recently that direct injections of adeno-associated viruses (AAV) into the colon, small intestine or cecum of rats and mice showed capsid and dose dependent targeting of myenteric and submucosal neurons and glia near the injection site. 2 We and others have recently shown that widespread ENS transduction is achieved in mice following a one-time systemic delivery of AAV8 or 9. 1,3 AAV9 targeted up to 57% of myenteric neurons from the stomach to the colon in mice following an intravenous AAV9 injection. 1 Similar transduction efficiency was also achieved in the murine submucosal plexus. 3 Guinea pigs are commonly used to model gut function and study gut physiology but, to our knowledge, no data exist on AAV transduction in the guinea pig ENS. 7, 8 Here we show that systemic injection of AAV8 or AAV9 targets myenteric and submucosal neurons in guinea pigs. Transgene expression occurred primarily in choline acetyltransferase (ChAT)-positive (myenteric plexus, MP) and vasoactive intestinal peptide (VIP)-positive (submucosal plexus, SMP) cells from the esophagus through the colon. Further, we demonstrate ENS transduction within the stomach, small intestine and large intestine of systemically injected cynomolgus macaques following intravenous AAV9 injection. These proof-ofprinciple data describe new tools to manipulate ENS gene expression in larger species and provide the foundation for future translation of an ENS directed gene therapy.
RESULTS

Systemic AAV targets guinea pig myenteric and submucosal plexuses
To examine AAV transduction efficiency and distribution in guinea pigs, we injected postnatal day 2 (P2) guinea pigs intravenously with either AAV8 or AAV9 vectors containing identical selfcomplementary (sc) GFP expression cassettes under the control of the chicken-β actin (CB) promoter which is designed to provide broad, sustained transgene expression. A pregnant sow (gestational day 50-53) was purchased and the litter of piglets was used in the study. Neither the sow nor the piglets were screened for anti-AAV antibodies. Two animals each received 2 × 10 12 vector genomes (vg) (2.8-3.4 × 10 13 vg per kg) of either scAAV8-CB-GFP or scAAV9-CB-GFP through the saphenous or cephalic vein while one animal received a phosphate-buffered saline (PBS) injection ( Table 1) . Four of five injected animals completed the 21-day study. One AAV8 injected animal (#101, Table 1 ) was euthanized at P5 due to dehydration and weight loss. Tissues from #101 were collected and analyzed identically to the remaining vector-treated animals. The remaining animals were euthanized at P21 and eyes, cochleae, brain, spinal cord, liver, lungs, spleen, heart, skeletal muscle (triceps, quadriceps, and gastrocnemius), bladder, gonads, kidneys, and the entire gastrointestinal tract were harvested for analysis. Our previous work showed dose dependent transduction of mouse myenteric plexus following AAV9 injection that reached up to 57% of myenteric neurons at the highest dose tested (1.3 × 10 14 vg per kg). 1 Dissection of the gastrointestinal tracts from AAV8 and AAV9 injected guinea pigs showed clear GFP expression in the myenteric plexus from the esophagus through the colon (Figure 1 ). GFP expression in the plexuses was fairly uniform throughout the given tissue, as opposed to 'hot spots' of single ganglion transduction. For AAV8-treated animals, the average number of GFP-positive cells in the myenteric plexus were distributed from most to fewest in the duodenum, jejunum, stomach, ileum, colon and cecum; esophagus was not quantified. In AAV9-treated animals the average number of GFP-positive cells were distributed from most to least in the duodenum, colon, jejunum, cecum, stomach and ileum. More replicates are required to determine if the distribution of GFP expression is reproducible. Differences in viral receptor expression likely explain the pattern of transgene expression within the tissues. In our study, GFPpositive cells were more abundant in AAV8-treated animals than AAV9 ( Table 2 ). GFP signal in both groups was most abundant in embryonic lethal abnormal vision (ELAV)-like proteins (HuD)positive cells indicating primarily neuronal transduction. 9 Anti-Hu antibody labels exclusively neurons in the ENS and has been tested in prior studies in guinea pigs and macaques. [10] [11] [12] [13] On average, neuronal transduction efficiency ranged from 3% in the cecum to 16% in the duodenum of the AAV8-treated animals. AAV9-mediated GFP expression ranged from 1.5% in the ileum to 5.5% in the duodenum. Percentages of GFP immunopositive HuDpositive MP neurons are listed in Table 2 . GFP-positive cells were present in the SMP of vector-treated guinea pigs from the duodenum through colon ( Figure 2 ). As in the myenteric plexus, GFP expression was found in HuD-positive neurons and not S100-positive intraganglionic glia (Figure 3a and b). Transduction of intraganglionic glia was not observed with either serotype in the myenteric or submucosal plexuses, though this is likely due to promoter usage. 1 SMP transduction in AAV8-treated animals ranged from a high of~28% in the jejunum to a low of 13% in the duodenum. AAV9 was less efficient at targeting SMP cells with a high of 5% in the duodenum to a low of 1% in the jejunum. Percentages of GFP immunopositive HuDpositive SMP neurons for each animal are listed in Table 2 .
Chemical coding of transduced ENS neurons In order to determine if AAV8 or AAV9 had a preference for any specific type of ENS neuron, longitudinal muscle-myenteric plexus (LMMP) preparations from colons of treated animals were immunolabeled for the neuron subtype markers ChAT, calbindin, calretinin, VIP and neuronal nitric oxide synthase (nNOS). In the MP, neuronal subtypes expressing ChAT include excitatory motor neurons projecting to circular and longitudinal muscles, ascending and descending interneurons, and some sensory neurons. 14 VIP and nNOS labeling occurs in inhibitory motor neurons projecting to circular and longitudinal muscles. 15 Calretinin expression occurs predominantly in ascending interneuron populations and less frequently in excitatory motor neurons. 16 Calbindin expression is commonly found in descending interneurons and sensory neurons. 15, 17 Classes of cholinergic (ChAT positive) and noncholinergic (VIP positive) secretomotor and vasodilator neurons are found in the SMP. 18 Calbindin immunoreactivity is detected in both secretomotor and vasodilator intrinsic primary afferent neurons. 19 Representative images from AAV8 animals are in Figure 3 . Counts within the specific cell types can be found in Table 3 . For example, of the VIP cells counted, a mean of 31% were GFP positive in AAV8 MP tissues. Piglet #101 that was euthanized at P5, had nearly 13% of VIP neurons expressed in GFP immunopositive neurons, while in piglet #102, euthanized at P21, had approximately 48% of VIP-positive neurons expressing GFP. In AAV9 tissues, between 12-13% of VIP cells were GFP positive. Within calbindin-positive cells, AAV8 targeted between 2-6% and AAV9 targeted between 0.9-3%. Representative images of ChAT, VIP and calbindin labeling in the SMP of AAV8-treated animals are shown in Figure 3b . The proportions of GFP-positive ChAT, VIP and calbindin SMP neurons counted in the ileum of vector-treated animals are in Table 3 . AAV8 targeted between 10 and 23% of VIP cells, 5 and 10% of calbindin cells and 12 and 29% Systemic injection of AAV8 and AAV9 targets neurons that innervate the GI tract Projections to the enteric nervous system can originate from neurons in the vagal nucleus, sacral spinal cord and dorsal root ganglia. 20 Therefore we examined innervating tissues for evidence of GFP expression in treated and control guinea pigs. Entire brains were sliced into coronal sections, collected in series and immunolabeled for GFP and cellular markers. Sections through the medulla of vector-treated guinea pigs showed GFP expression within ChAT-positive neuronal cells in the MN X nucleus ( Figure 4 ). Brains of AAV8-treated guinea pigs had GFP-positive cells scattered throughout. Representative images from cortex, hippocampus, striatum and cerebellum are shown in Supplementary Figure S1 . Co-labeling with markers for neurons (NeuN), oligodendrocytes (CC1) and astrocytes (GFAP) revealed AAV8 targeting of all three cell types (Supplementary Figure S2 ). Brains from AAV9treated animals also had scattered GFP-positive cells throughout, but expression was confined to neurons and astrocytes ( Supplementary Figures S1 and S2 ). Dorsal root ganglia (DRG) were harvested and immunolabeled for GFP expression from vector-treated animals. GFP expression was detected in cells with neuronal morphology within DRG of both AAV8-( Figure 4 ) and AAV9-(not shown) treated animals. In the spinal cords of vectortreated animals, GFP expression was detected in fibers in dorsal horns and dorsal columns in the cervical, thoracic and lumbar regions of the spinal cord (Supplementary Figure S3 ). This pattern of expression is consistent with DRG neuronal transduction. GFP expression was absent from S100-positive cells in DRG indicating a lack of gene expression within satellite glial cells. 21 Systemic injection of AAV vectors in guinea pigs results in widespread gene expression throughout the body Gene delivery studies in mice, rats and non-human primates show that systemic AAV targets multiple tissues including liver and Immunolabeling in the myenteric plexus (a) reveals that AAV targets ChAT, VIP, calbindin, calretinin and nNOS neurons. We did not observe AAV transduction of S100-positive intraganglionic glial cells in either the MP (a) or SMP (b). skeletal and cardiac muscle, but we are unaware of distribution studies in guinea pigs. [22] [23] [24] Therefore we examined GFP immunofluorescence in multiple tissues from AAV8, AAV9 and control treated guinea pigs. Scattered GFP-positive cells were detectable in lung, kidney, spleen and liver of both vector-treated cohorts but not the control treated animal (Supplementary Figure S4 ). AAV mediated gene delivery to skeletal muscle is well documented in rodents, dogs, non-human primates and humans with multiple AAV serotypes. 25 To determine whether skeletal muscle was transduced in guinea pigs, gastrocnemius and triceps muscles from control and vector-treated animals were examined for GFP expression. Surprisingly, GFP expression in skeletal muscle was detected only sporadically and only in one AAV9-treated animal (Supplementary Figure S4 ). Cardiac muscle also had evidence of GFP-positive cells in AAV8 and AAV9-treated animals. Besides the ENS, guinea pigs are used in studies of vision and hearing. [26] [27] [28] [29] AAV vectors transduce retinal and cochlear tissues in other species following systemic or direct injections. [30] [31] [32] [33] However, we found no evidence that systemic injection of either AAV8 or AAV9 resulted in GFP expression in guinea pig retina or cochlea (not shown). No GFP expression was detected in any tissues from the PBS-treated animal.
Systemic AAV9 transduces the myenteric plexus in cynomolgus macaques The targeting of ENS cells throughout the gastrointestinal (GI) tract in guinea pigs lays the foundation for the development of novel therapeutic strategies to modulate barrier function, inflammation or visceral pain using gene delivery. [34] [35] [36] An important step in therapeutic development is the translation of therapeutic delivery to higher order species. It has been shown that systemic AAV9 targets enteric neurons in the gut of nonhuman primates, but those data were obtained from intestinal cross sections and provide no information on distribution along the GI tract or the types of neurons targeted. 33 Therefore, we obtained archived tissues samples from previous work to better characterize AAV9 transduction in non-human primates. 22 Archived samples from AAV8-treated non-human primates were not available. Cynomolgus macaques (n = 3) received systemic injections of 1-3 × 10 14 vg per kg scAAV9 containing the same expression construct as the treated guinea pigs. Animals were euthanized approximately 21-24 days post injection and flushed with PBS and 4% paraformaldehyde pH 7.4. Tissue segments were collected from the stomach, small intestine and large intestine and were held in 4% paraformaldehyde (pH 7.4) until analysis. GI tissue sampling during harvest was not uniform across animals leading to sampling of different intestinal regions. Therefore we did not quantify ENS transduction in NHP tissues. LMMP preparations from the stomach, small intestine and large intestine reveal GFP expression within HuD-positive cells ( Figure 5 ). There was no evidence of GFP expression in S100 cells (not shown) or longitudinal muscle. Together, these data indicate a consistent neuronal pattern of transduction across species with AAV9. On the basis of the sections examined, GFP-positive cells were more abundant in the small and large intestine compared to the stomach. GFP expression was most often found in ChAT-positive neurons and co-localization with other neuronal markers calbindin, calretinin, nNOS and VIP were infrequent or never observed ( Figure 6 ).
DISCUSSION
Our previous work applied systemic delivery of multiple AAV serotypes to newborn and juvenile mice to determine transduction efficiency of the myenteric plexus. 1 Those data showed that efficient targeting of myenteric neurons was achieved with AAV8 and AAV9 vectors in all regions examined (stomach to colon). Neuronal targeting included ChAT, calretinin and calbindinpositive cells, but not VIP or nNOS cells. Transgene expression in S100-positive enteric glial cells was rare but influenced by viral capsid and expression cassette. 1 These findings were largely replicated and furthered by showing transduction in the submucosal plexus in mice. 3 Here we demonstrate proof of concept that systemic delivery of AAV vectors can target the enteric nervous system in guinea pigs and non-human primates. Across our studies, mice and guinea pigs were given similar vector doses (~3 × 10 13 vg per kg) with~16-20% of myenteric neurons targeted in mouse colon and 4-6% in guinea pigs. 1, 3 At least for AAV8, this difference in efficiency is partially due to one AAV8 guinea pig not completing the study since a longer time post injection increases the accumulation of GFP and therefore the sensitivity of detection. Guinea pig #101 may have died prematurely because high GFP expression can cause acute liver toxicity. GFP expression was detected in the liver from #101 in native and stained tissues, but no further toxicological analysis was performed. Buckinx et al. 3 reported 22-29% targeting of myenteric neurons in mice following IV injection of~1.3 × 10 13 vg per kg AAV8 or AAV9. The different efficiencies may be due to their use of the CMV promoter versus the CB promoter in our studies. Future work should directly examine the role of the viral expression cassette in enhancing or narrowing the pattern of transduction by comparing the CMV and CB promoters and including cell type specific promoters. 37, 38 Buckinx and group also reported SMP neuron transduction in mice that ranged from 23-28% in the ileum and 5-12% in the colon following IV AAV8 or AAV9 injections. 3 In the current study, SMP transduction ranged from 13-28% in the small intestine and 14-23% in the cecum and colon for AAV8-treated guinea pigs. AAV9-treated guinea pigs had considerably fewer transduced neurons in the SMP in all regions examined (~1-5%). Despite subtle differences between the current and Buckinx studies, the transduction efficiency for AAV8 in both enteric plexuses is remarkably similar across species. It is unclear why SMP was more efficiently targeted than MP in AAV8-treated guinea pigs but not AAV9-treated animals. This may be due to different distributions of co-receptors for AAV8 and AAV9. 39, 40 It is also important to note that the ENS transduction in this study is from animals that received AAV injections during their first few days (guinea pigs) or weeks (NHP) of life. We previously reported different transduction patterns in the CNS of mice that received injections as neonates or adults. 41 Interestingly, ENS transduction in mice remained consistent across age. 1 Transgene expression should persist to adulthood in non-dividing cells, future work should document transduction when vector is administered to adult animals. AAV9 has been extensively studied for its ability to cross the blood brain barrier and efficiently transduce the CNS of mice, rats, cats and non-human primates. 22, 24, [41] [42] [43] The data remain consistent across groups and species and supported the Phase I/II testing of systemic AAV9 delivery for the pediatric neuromuscular disease spinal muscular atrophy (SMA) (clinicaltrials.gov #NCT02122952). Therefore the drop in AAV9 CNS and ENS transduction in guinea pigs compared to mice is surprising though species differences in AAV transduction have been reported for other serotypes including AAV8. 44, 45 Preliminary data from the SMA clinical trial indicate safety and therapeutic efficacy at doses above those tested here (2 × 10 14 vg per kg) suggesting that systemically injected AAV9 targets the CNS in humans. 46 The safety of the higher AAV9 dose currently in clinical testing supports increasing the viral dose in animals which should enhance ENS transduction. Increased viral doses are also supported by our earlier work in mice where doses ranging from 6.7 × 10 13 to 1 × 10 14 vg per kg transduced 25-57% of myenteric neurons depending on gastrointestinal region examined. 1 These data are important because they are the foundation for the use of AAV gene delivery as a novel tool and/or therapeutic for the ENS.
Currently, viral gene delivery is used sparingly to target the ENS. This is partially because means of viral delivery to ENS cells has not been thoroughly examined. In the ENS, AAV gene delivery can be used for classical experiments like neuronal tracing and with emerging technologies like optogenetics and gene editing. [47] [48] [49] Our work shows that it is now feasible to bring these technologies into large animal models of the ENS. An advantage of vectormediated gene delivery is that the ease of use and kinetics of AAV mediated gene delivery offer temporal control of transgene expression in target cells. AAV vectors infect both dividing and non-dividing cells but only persist in non-dividing cells. 50 Once inside, recombinant AAV genomes largely persist as stable episomes that can produce transgene expression for the life of the cell. 51 In the CNS, AAV vectors infect a variety of cells including neurons, astrocytes, oligodendrocytes, endothelial cells and ependymal cells. 41, 52, 53 We previously reported extensive CNS astrocyte transduction in mice and non-human primates using the identical AAV9 construct as this study. 22, 41 Here we show targeting of CNS astrocytes, neurons and oligodendrocytes with AAV8 in guinea pigs ( Supplementary Figures S1 and S2) . In the ENS, Figure 6 . ChAT and Calbindin myenteric neurons are targeted by systemic AAV9 in non-human primates. Sections from AAV9-treated cynomolgus macaque small intestine, prepared by LMMP dissection to expose the myenteric plexus, were labeled for GFP (green) and ChAT, Calbindin, Calretinin, nNOS, VIP or S100 (all in red, first column) and examined for co-localization by confocal microscopy. GFP was detected within ChAT-positive and Calbindin-positive neurons but not within other cell types. Scale bars = 100 μm.
transduction was limited to neurons, with VIP and ChAT staining being the most abundant within plexuses. The limited enteric glial transduction observed across species remains puzzling. The emerging roles of enteric glia in gut homeostasis and pathology make them an important target cell. 34, 54 The ability to customize the AAV vector through changes to the viral capsid and/or expression cassette are important tools for future targeting of enteric glia and other types of enteric neurons. Further investigation of AAV promoter and capsid type is required to alter expression in specific cell types, however our work demonstrates that delivery is feasible in larger animal models. In addition to the 4100 naturally occurring capsids available for testing, unbiased evolution strategies that rapidly screen entire libraries for enhanced transduction of a target cell are now available. 55, 56 As mentioned above, the expression cassette encoded by the recombinant AAV genome can include cell type specific promoters and/or miRNA binding sites to further specify transgene expression once inside a target cell. 38 More work is required to identify capsid/expression cassette combinations that target more cells within the ENS. Novel capsid evolution or mutagenesis techniques could also be applied for a more directed enhancement of ENS transduction. This work is the initial steps in examining viral gene therapy potential in the ENS.
A crucial step to therapy development is to ensure that the therapy reaches the intended target. In this work, we advance gene delivery for the ENS by providing proof-of-concept data that non-invasive, widespread targeting of ENS cells is possible in guinea pigs and non-human primates. In primates, GFP expression was detected in ChAT-positive and calbindin-positive neurons suggesting that vector targeted intrinsic primary afferent neurons, descending interneurons and/or circular muscle excitatory motor neurons. It is likely that the transduction in non-human primates shown here represents an underestimation because tissue collection and storage in the original study was not optimized for gut dissection. Unfortunately, this also limited analysis of SMP transduction. Future studies should include the SMP and more extensive co-labeling, tracing and potentially cell extraction to better characterize transduction. Finally, NHP GI tissues were not uniformly harvested which limited our ability to quantify transduction.
In conclusion, we have shown that AAV gene delivery to the ENS is translatable from mice to the commonly used guinea pig and cynomolgus macaque. The potential exists for this approach to allow for spatial and temporal control of target gene expression and/or knockdown within a percentage of cells in the ENS, and describes an important tool for the study and treatment of the ENS in larger species.
MATERIALS AND METHODS
Ethics statement
This study was approved by the Ohio State University Institutional Laboratory Animal Care and Use Committee (Protocol #2011A00000100R1). All animal procedures (non-surgical injection and killing) were performed to minimize animal discomfort. Piglet injection procedures were performed under 1% isoflurane anesthesia and are described below. Piglet euthanasia procedures were performed in consultation with OSU animal care veterinary staff and are described below.
Animals and tissue samples
A pregnant guinea pig sow (50-60 days gestation), purchased from Hilltop Lab (Scottdale, PA, USA), delivered three female and two male guinea piglets. Piglets were intravenously injected on postnatal day 2 (P2) with AAV vectors described in 'Vector Production and Purification' (also Table 1 ). Following vector injection, piglets remained with the sow until P21. Guinea pigs were given standard food and water ad libitum in a 12 h light/dark cycle rooms in the vivarium. Cynomologus macaque (Macaca fasciculata, n = 3) GI tissues were from the laboratory of Dr Brian Kaspar (Nationwide Children's Hospital) and arrived fixed in 4% paraformaldehyde pH 7.4. For a detailed description of monkey procedures and AAV9 transduction outside the ENS refer to Bevan et al. 22 Briefly, primates were injected in the saphenous vein with 3 × 10 14 vg per kg of AAV9 CB GFP at ages P1, P30 or P90. All subjects were killed and transcardially perfused 21-24 days post vector injection.
Vector production and purification AAV vectors used in these studies were identical to those previously described. 1 Briefly, AAVs were produced by the University of Massachusetts Medical School Viral Vector Core. Self-complementary AAV (scAAV) genomes were engineered to encode for GFP transgene under the control of the chicken beta actin/cytomegalovirus hybrid (CB) promoter, flanked by AAV2 inverted terminal repeats. Virus was packaged in HEK293 cells with plasmids containing AAV2 rep genes and AAV8 or nine cap genes. Cesium chloride gradient was used to purify the vector and titers were determined by qPCR. Vector titers for scAAV8 and scAAV9-CB-GFP were 1 × 10 13 vg per ml.
AAV injections in neonatal guinea pigs
Neonatal guinea pigs were injected on P2 in the saphenous or cephalic vein with either scAAV8-CB-GFP (n = 2) or scAAV9-CB-GFP (n = 2) of 2 × 10 12 vg. Injections were performed by the vet staff. Piglets were anesthetized with isoflurane prior to injection. Injection areas were then shaved and swabbed with isopropyl alcohol. A 28 gauge needle was used to inject 200 μl of virus into each piglet, resulting in final doses of 2.8-3.1 × 10 13 vg per kg for scAAV8-CB-GFP and 2.8-3.4 × 10 13 vg per kg for scAAV9-CB-GFP piglets. The first piglet injected with scAAV8-CB GFP was found laterally recumbent on P5 due to indeterminate cause and was euthanized as described below. All other treated piglets completed the study without incident.
Guinea pig euthanasia and tissue preparation
All piglets were euthanized by ketamine/xylazine intraperitoneal injection and transcardiac perfusion with a PBS rinse and 4% paraformaldehyde (PFA) pH 7.4 for fixation by lab staff according to IACUC approved protocols. Tissues collected from piglets included eyes, cochleae, brain, spinal cord with dorsal root ganglia, liver, lungs, spleen, heart, skeletal muscle (triceps, quadriceps and gastrocnemius), bladder, gonads, kidneys, and the entire gastrointestinal tract. The gastrointestinal tract was pinned flat in Zamboni's fixative prior to further dissection. Dissection of the ENS is described in the following section.
Brains were post-fixed in 4% paraformaldehyde pH 7.4 for 48 h before cryoprotection then sliced into 40μm coronal sections on a sliding microtome. Paraformaldehyde fixed sections from the cervical, thoracic, and lumbar spinal cord were sliced at 40 μm on a vibratome. Paraformaldehyde fixed liver, lung, kidney, spleen, heart and all skeletal muscles were cut 40 μm thick on a vibratome. Bladder, testes, and ovaries were flash frozen and sliced at 25 μm on a cryostat, and sections were collected on slides. For cochlear tissue analysis, the fixed cochleae were initially removed from the temporal bones of the guinea pigs. Under a dissection microscope, the cochleae were dissected in PBS. The bony portion of each cochlea was removed to expose the membranous portion of the cochlea underneath. The membranous portion included the basilar membrane with the organ of Corti on top and the lateral wall, which consists of the stria vascularis and spiral ligament. The basilar membrane is anchored to the central bony core of the cochlea, the modiolus. The modiolus was sectioned horizontally to create three segments of modiolus, basilar membrane, and lateral wall. The three segments were from the basal, middle, and apical turns of the cochlea. Cochleae were then fixed in formalin and sliced at 15 μm on a cryostat.
Whole mount preparations of the ENS
Guinea pig. Whole mount longitudinal muscle-myenteric plexus (LMMP) and submucosal plexus (SMP) preparations from guinea pig tissue were dissected as previously described. 1 Briefly, the entire gastrointestinal tract from the esophagus to the rectum was removed from euthanized guinea pigs and placed in room temperature (RT) PBS. Sections from all regions of the GI tract including the esophagus, stomach, duodenum, jejunum, ileum, cecum and both proximal and distal sections of the colon were placed in a dish lined with a silicone elastomer and filled with cold PBS, opened along the line of the mesenteric attachment, and pinned flat so that the mucosal layer was closest to the surface. Tissues were fixed overnight at 4˚C in Zamboni's fixative. The next day, tissues were rinsed 5 × in RT PBS. For LMMP preparations, the mucosa, submucosa, and circular muscle layers were gently removed with fine-tipped forceps under a stereoscope to revel the myenteric plexus atop the longitudinal muscle. For SMP preparations, the mucosa was gently peeled away and the tissue was flipped over and re-pinned. Afterward the longitudinal muscle, MP, and circular muscle were removed to expose the SMP. Dissected sections went on to immunofluorescent labeling.
Cynomologus macaque
Whole mount LMMP preparations were dissected like the guinea pig. NHP gastrointestinal tissues were previously fixed in 4% paraformaldehyde pH 7.4 in their original tubular orientation. Pieces of the small intestine, large intestine, and stomach were rinsed in PBS and pinned flat. For LMMP preparations, muscosal, submucosal and circular muscle layers were removed to expose the MP. Dissected sections were then immunofluorescently labeled. The protocol for immunolabeling is below.
Immunolabeling Immunofluorescent or chromogen staining was used to detect GFP expression in tissues. Chromogen detection was the preferred method of staining in tissues with high levels of autofluorescence. All tissues were stained as free-floating sections except those sliced on the cryostat (Tissue Preparation section). All antibodies and their concentrations used for each tissue are listed in Supplementary S1 Table. Tissues were washed with PBS prior to blocking (blocking solution: 10% normal donkey serum, 1% Triton-X 100, PBS) for 2 h at RT then incubated in primary antibody diluted in blocking solution (24-72 h) at 4°C. Next, tissues were rinsed three times with PBS before incubation in secondary antibody in blocking solution for 2 h at RT. Following final PBS rinses, sections were mounted or coverslipped using PVA/DABCO mounting media.
For labeling of macaque GI tissue, antigen retrieval was performed by incubating tissues in 1 mM ethylenediaminetetraacetic acid (EDTA) for 20 min at 90°C. Tissues were then rinsed in cold tap water and incubated overnight in blocking solution at 4°C. Primary antibody (diluted in blocking solution) incubation occurred over the following night. After PBS rinses, the tissue was re-incubated in blocking solution at RT for 2 h prior to secondary antibody (diluted in blocking solution) incubation for 2 h at RT. Sections were rinsed then mounted and coverslipped using PVA/DABCO mounting media.
For chromogen staining: tissues were rinsed three times in fresh PBS and incubated in blocking solution (10% normal donkey serum, 1% Triton-X 100, PBS) for 2 h at RT. All antibody incubations were performed in blocking solution. Primary antibody was applied overnight and tissues were rinsed in PBS the following day. Secondary antibody was applied for 2 h at RT, followed by three rinses in PBS. Tissues were then incubated in ABC solution per the kit instructions (Vector Labs, Burlingame, CA, USA) for 2 h at RT and tissues were rinsed again with PBS. Finally, tissues were developed using 3′,3′-Diaminobenzidine. Free-floating tissue sections were mounted on glass slides, dehydrated and coverslipped with Cytoseal (Thermo Scientific, Waltham, MA, USA).
Quantification of ENS neurons
Quantification of neurons in the submucosal and myenteric plexus of the guinea pig was completed as previously described. 1 Briefly, fluorescently stained whole mount LMMP or SMP tissues were viewed with a Zeiss fluorescent microscope equipped with filters for CY3, CY5 and FITC fluorophores. Cells were counted by an experienced investigators (SEG, CJC and MGN) blind to the treatment groups. Prior to quantification, levels of autofluorescence and background fluorescence were examined in stained and unstained naïve and PBS injected tissues. No auto-or background fluorescence was apparent in enteric neurons or glial cells in piglet or primate tissues, therefore, neurons were considered GFP positive if they expressed any level of FITC fluorescence. MP and SMP ganglia were viewed with a × 40 objective for counting. GFP-positive and HuD-positive neurons were counted in the MP of the stomach, duodenum, jejunum, ileum, cecum, and colon. In the SMP, GFP-positive and HuD-positive neurons were counted in all GI regions except the stomach. Transduction efficiency of enteric neurons positive for VIP, calretinin, calbindin, nNOS or ChAT and GFP were recorded in the MP of ileal sections only. Total neuron counts are recorded in Supplementary Table S2 . Data is reported as the percentage of GFP-positive neurons ± s.e.m.
Sample size and data analysis
Due to the nature of this exploratory study and the consequent low sample size, statistical analysis was deemed inappropriate and was not completed. The investigator responsible for quantification of transduced neurons was blind to which animal was being investigated and what vector type each animal had been injected with. There was a total of five guinea piglets used in this study (Table 1 ) and gastrointestinal tissue from three macaques was examined. All animals were included in this study, and the piglet to receive either vector type or a control injection was chosen at random. A single piglet receiving an AAV8 injection was euthanized due to failing health on postnatal day 5. Due to this abnormality between samples, data is listed for each animal individually in Tables 1 and 2. 
